Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2015 2
2016 2
2017 1
2019 1
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.
Burger JA. Burger JA. Curr Hematol Malig Rep. 2014 Mar;9(1):44-9. doi: 10.1007/s11899-013-0188-8. Curr Hematol Malig Rep. 2014. PMID: 24357428 Review.
Other BTK inhibitors in earlier clinical development include CC-292 (AVL-292), and ONO-4059. In CLL and MCL, ibrutinib characteristically induces redistribution of malignant B cells from tissue sites into the peripheral blood, along with rapid resolution of enlarged …
Other BTK inhibitors in earlier clinical development include CC-292 (AVL-292), and ONO-4059. In CLL and MCL, ibrutinib charact …
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Robak T, Robak E. Robak T, et al. Expert Opin Investig Drugs. 2012 Jul;21(7):921-47. doi: 10.1517/13543784.2012.685650. Epub 2012 May 22. Expert Opin Investig Drugs. 2012. PMID: 22612424 Review.
The search terms used were Bruton's tyrosine kinase (Btk) inhibitors, PCI-32765, GDC-0834, LFM-A13, AVL-101, AVL-292, spleen tyrosine kinase (Syk) inhibitors, R343, R406, R112, R788, fostamatinib, BAY-61-3606, C-61, piceatannol, Lyn, imatinib, nilotinib, bafetinib, …
The search terms used were Bruton's tyrosine kinase (Btk) inhibitors, PCI-32765, GDC-0834, LFM-A13, AVL-101, AVL-292, spleen t …
Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function.
Zheng TJ, Lofurno ER, Melrose AR, Lakshmanan HHS, Pang J, Phillips KG, Fallon ME, Kohs TCL, Ngo ATP, Shatzel JJ, Hinds MT, McCarty OJT, Aslan JE. Zheng TJ, et al. Am J Physiol Cell Physiol. 2021 May 1;320(5):C902-C915. doi: 10.1152/ajpcell.00296.2020. Epub 2021 Mar 10. Am J Physiol Cell Physiol. 2021. PMID: 33689480 Free PMC article.
These inhibitors include four Syk inhibitors, Bay 61-3606, R406 (fostamatinib), entospletinib, TAK-659; four irreversible BTK inhibitors, ibrutinib, acalabrutinib, ONO-4059 (tirabrutinib), AVL-292 (spebrutinib); and four reversible BTK inhibitors, CG-806, BMS-935177 …
These inhibitors include four Syk inhibitors, Bay 61-3606, R406 (fostamatinib), entospletinib, TAK-659; four irreversible BTK inhibitors, ib …
BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils.
Smiljkovic D, Blatt K, Stefanzl G, Dorofeeva Y, Skrabs C, Focke-Tejkl M, Sperr WR, Jaeger U, Valenta R, Valent P. Smiljkovic D, et al. Allergy. 2017 Nov;72(11):1666-1676. doi: 10.1111/all.13166. Epub 2017 Apr 20. Allergy. 2017. PMID: 28328081 Free PMC article.
METHODS: We examined the effects of four BTK inhibitors (ibrutinib, dasatinib, AVL-292, and CNX-774) on IgE-dependent activation and histamine release in blood basophils obtained from allergic patients (n=11) and nonallergic donors (n=5). ...Dasatinib and ibrutinib …
METHODS: We examined the effects of four BTK inhibitors (ibrutinib, dasatinib, AVL-292, and CNX-774) on IgE-dependent activati …
BTK Isoforms p80 and p65 Are Expressed in Head and Neck Squamous Cell Carcinoma (HNSCC) and Involved in Tumor Progression.
Betzler AC, Strobel H, Abou Kors T, Ezić J, Lesakova K, Pscheid R, Azoitei N, Sporleder J, Staufenberg AR, Drees R, Weissinger SE, Greve J, Doescher J, Theodoraki MN, Schuler PJ, Laban S, Kibe T, Kishida M, Kishida S, Idel C, Hoffmann TK, Lavitrano M, Grassilli E, Brunner C. Betzler AC, et al. Cancers (Basel). 2023 Jan 3;15(1):310. doi: 10.3390/cancers15010310. Cancers (Basel). 2023. PMID: 36612306 Free PMC article.
Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X, Wong J, Sevinsky CJ, Kokabee L, Khan F, Sun Y, Conklin DS. Wang X, et al. Mol Cancer Ther. 2016 Sep;15(9):2198-208. doi: 10.1158/1535-7163.MCT-15-0813. Epub 2016 Jun 2. Mol Cancer Ther. 2016. PMID: 27256378 Free PMC article.
In this study, we show that recently developed inhibitors of BTK, such as ibrutinib (PCI-32765), AVL-292, and CGI-1746, reduce breast cancer cell survival and prevent drug-resistant clones from arising. ...HER2(+) breast cancer cell proliferation is blocked by ibrut …
In this study, we show that recently developed inhibitors of BTK, such as ibrutinib (PCI-32765), AVL-292, and CGI-1746, reduce …
Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.
Kokabee L, Wang X, Sevinsky CJ, Wang WL, Cheu L, Chittur SV, Karimipoor M, Tenniswood M, Conklin DS. Kokabee L, et al. Cancer Biol Ther. 2015;16(11):1604-15. doi: 10.1080/15384047.2015.1078023. Epub 2015 Sep 18. Cancer Biol Ther. 2015. PMID: 26383180 Free PMC article.
Down regulation of this protein with RNAi or inhibition with BTK-specific inhibitors, Ibrutinib, AVL-292 or CGI-1746 decrease cell survival and induce apoptosis in prostate cancer cells. ...
Down regulation of this protein with RNAi or inhibition with BTK-specific inhibitors, Ibrutinib, AVL-292 or CGI-1746 decrease …
Optimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression.
Kim E, Yang KS, Kohler RH, Dubach JM, Mikula H, Weissleder R. Kim E, et al. Bioconjug Chem. 2015 Aug 19;26(8):1513-8. doi: 10.1021/acs.bioconjchem.5b00152. Epub 2015 Jun 9. Bioconjug Chem. 2015. PMID: 26017814 Free PMC article.
To develop robust companion imaging diagnostics for in vivo use, we set out to explore the effects of red wavelength fluorochrome modifications of two highly potent irreversible Btk inhibitors, Ibrutinib and AVL-292. Surprisingly, we found that subtle chemical diffe …
To develop robust companion imaging diagnostics for in vivo use, we set out to explore the effects of red wavelength fluorochrome modificati …
Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold.
Ge Y, Jin Y, Wang C, Zhang J, Tang Z, Peng J, Liu K, Li Y, Zhou Y, Ma X. Ge Y, et al. ACS Med Chem Lett. 2016 Sep 21;7(12):1050-1055. doi: 10.1021/acsmedchemlett.6b00235. eCollection 2016 Dec 8. ACS Med Chem Lett. 2016. PMID: 27994736 Free PMC article.
The activity of the subject compound as determined by the CCK-8 method and apoptosis analysis validated that inhibitor 10j is slightly more potent than AVL-292 and ibrutinib. The results of these experimental explorations suggested that 10j could serve as a valuable …
The activity of the subject compound as determined by the CCK-8 method and apoptosis analysis validated that inhibitor 10j is slightly more …
Influence of Bruton's Tyrosine Kinase (BTK) on Epithelial-Mesenchymal Transition (EMT) Processes and Cancer Stem Cell (CSC) Enrichment in Head and Neck Squamous Cell Carcinoma (HNSCC).
Leichtle F, Betzler AC, Eizenberger C, Lesakova K, Ezić J, Drees R, Greve J, Schuler PJ, Laban S, Hoffmann TK, Cordes N, Lavitrano M, Grassilli E, Brunner C. Leichtle F, et al. Int J Mol Sci. 2023 Aug 23;24(17):13133. doi: 10.3390/ijms241713133. Int J Mol Sci. 2023. PMID: 37685940 Free PMC article.
Treatment of HNSCC-derived cell lines cultured under 3D conditions with the BTK inhibitor AVL-292 caused reduced sphere formation, which was accompanied by reduced numbers of ALDH1A1(+) CSCs as well as biological changes associated with the EMT. ...
Treatment of HNSCC-derived cell lines cultured under 3D conditions with the BTK inhibitor AVL-292 caused reduced sphere format …
11 results